BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Week In Review | Aug 4, 2017
Clinical News

Quark's QPI-1002 meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) reported data from a Phase II trial in 341 patients at high risk of acute kidney injury (AKI) following cardiac surgery showing that a single dose of IV QPI-1002 met...
BC Extra | Jul 27, 2017
Clinical News

Quark siRNA meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) said QPI-1002 met the primary endpoint in a Phase II trial to prevent acute kidney injury (AKI) following cardiac surgery. Novartis AG (NYSE:NVS; SIX:NOVN) has an option to obtain exclusive,...
BC Week In Review | Mar 21, 2016
Clinical News

QPI-1002: Phase III started

SBI’s Quark Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase III ReGIFT trial to evaluate single doses of IV QPI-1002 in about 634 patients. Quark granted Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) an option...
BC Week In Review | Mar 21, 2016
Clinical News

QPI-1002: Phase II started

SBI’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, North American Phase II trial to evaluate single doses of IV QPI-1002 in about 340 patients. Quark granted Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) an option...
BC Week In Review | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase II/III trial to evaluate 1.5 and 3 mg QPI-1007 per eye given as a single intravitreal injection or as 3 injections 2 months...
BC Week In Review | Aug 4, 2014
Clinical News

QPI-1002: Phase II data

Data from 327 evaluable end-stage kidney disease dialysis-dependent patients undergoing deceased donor kidney transplantation in the Phase II portion of the double-blind, international Phase I/II QRK.006B trial showed that a single IV dose of 10...
BC Extra | Jul 29, 2014
Clinical News

QPI-1002 misses in graft function Phase II

The Quark Pharmaceuticals Inc. subsidiary of SBI Biotech Co. Ltd. (Tokyo, Japan) said a single IV dose of QPI-1002 missed the primary endpoint vs. placebo in the Phase II portion of the Phase I/II QRK.006B...
BC Innovations | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
Items per page:
1 - 10 of 67
BioCentury | Apr 8, 2020
Finance

Suzhou Ribo raises $66.3M for nucleic acid therapies

Four months after closing a RMB203 million ($28.8 million) series C round, Suzhou Ribo Life Science Co. Ltd. has raised an additional RMB470 million in a series C2 round to advance its RNAi and antisense...
BioCentury | Feb 22, 2020
Product Development

Regenerative medicine for hearing loss makes quiet progress

While the late-stage programs for hearing loss are designed to protect cells in the inner ear, or help them recover from trauma, a growing number of early-stage therapies is aiming for a more dramatic outcome...
BC Week In Review | Aug 4, 2017
Clinical News

Quark's QPI-1002 meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) reported data from a Phase II trial in 341 patients at high risk of acute kidney injury (AKI) following cardiac surgery showing that a single dose of IV QPI-1002 met...
BC Extra | Jul 27, 2017
Clinical News

Quark siRNA meets Phase II kidney injury endpoint

Quark Pharmaceuticals Inc. (Fremont, Calif.) said QPI-1002 met the primary endpoint in a Phase II trial to prevent acute kidney injury (AKI) following cardiac surgery. Novartis AG (NYSE:NVS; SIX:NOVN) has an option to obtain exclusive,...
BC Week In Review | Mar 21, 2016
Clinical News

QPI-1002: Phase III started

SBI’s Quark Pharmaceuticals Inc. subsidiary began the double-blind, placebo-controlled, international Phase III ReGIFT trial to evaluate single doses of IV QPI-1002 in about 634 patients. Quark granted Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) an option...
BC Week In Review | Mar 21, 2016
Clinical News

QPI-1002: Phase II started

SBI’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, placebo-controlled, North American Phase II trial to evaluate single doses of IV QPI-1002 in about 340 patients. Quark granted Novartis AG (NYSE:NVS; SIX:NOVN, Basel, Switzerland) an option...
BC Week In Review | Nov 9, 2015
Clinical News

QPI-1007: Phase II/III started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase II/III trial to evaluate 1.5 and 3 mg QPI-1007 per eye given as a single intravitreal injection or as 3 injections 2 months...
BC Week In Review | Aug 4, 2014
Clinical News

QPI-1002: Phase II data

Data from 327 evaluable end-stage kidney disease dialysis-dependent patients undergoing deceased donor kidney transplantation in the Phase II portion of the double-blind, international Phase I/II QRK.006B trial showed that a single IV dose of 10...
BC Extra | Jul 29, 2014
Clinical News

QPI-1002 misses in graft function Phase II

The Quark Pharmaceuticals Inc. subsidiary of SBI Biotech Co. Ltd. (Tokyo, Japan) said a single IV dose of QPI-1002 missed the primary endpoint vs. placebo in the Phase II portion of the Phase I/II QRK.006B...
BC Innovations | Jul 24, 2014
Cover Story

It is an RNA world

RNA-based molecules have redefined the universe of tractable targets by putting virtually anything that is gene encoded within reach of a disease-modifying agent. This redefinition has launched RNA as the biotech industry's third drug modality....
Items per page:
1 - 10 of 67